Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 95, Issue 1, Pages 32-44Publisher
WILEY
DOI: 10.1038/clpt.2013.196
Keywords
-
Categories
Funding
- National Institutes of Neurological Disorders and Stroke (NINDS)
- Mayo Clinic Center for Translational Science Activities
- National Center for Advancing Translational Science (NCATS), a component of the National Institutes of Health
- Minnesota Partnership Award for Biotechnology and Medical Genomics
- Applebaum Foundation
- Hilton Foundation
- Peterson Foundation
- Sanford Foundation
- McNeilus family
- NINDS
- US Department of Defense
- Novartis Pharmaceuticals
Ask authors/readers for more resources
We provide a focused review of novel immunomodulatory approaches for the treatment of multiple sclerosis, the most common acquired inflammatory demyelinating disease of humans. The requirement for such a review was stimulated by the emerging application of novel,oral medications and the need for the practicing physician to place these within the treatment paradigm. We provide a conceptual diagram of our current view of the pathogenesis of demyelination and remyelination in this disorder. In addition, we include a working template on how to use a tier 1 and tier 2 approach to medications as the disease worsens in the individual. We emphasize the approach of treatment based on individualized medicine, tailored to the specific needs of each patient. In the future, we envision new drugs to enhance remyelination and protect neurons and axons from death in order to promote central nervous system regeneration and repair.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available